PharmaCore Biotech Co., Ltd.

Primary objective: To evaluate the safety of multiple administrations of LT3001 for injection in the treatment of patients with acute ischemic stroke (AIS). Secondary objective: To evaluate the effectiveness of multiple administrations of LT3001 for injection in the treatment of patients with acute ischemic stroke (AIS).

Primary purpose: To evaluate the safety and tolerability of LBL-007 combined with Teplizumab in the treatment of advanced malignant tumors and determine the recommended dose for Phase II; (Phase Ib) To evaluate the effectiveness of LBL-007 combined with Teplizumab in the treatment of advanced malignant tumors. (Phase II) Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of LBL-007 combined with Teplizumab in the treatment of advanced malignant tumors; To evaluate the immunogenicity of LBL-007 combined with Teplizumab in the treatment of advanced malignant tumors; To evaluate the safety of LBL-007 combined with Teplizumab in the treatment of advanced malignant tumors. Exploratory purpose: Correlation between the expression of lymphocyte activation gene-3 (LAG-3) and programmed death receptor-ligand 1 (PD-L1) in tumor tissue and clinical efficacy; Peripheral blood LAG-3 receptor occupancy (RO) rate.

Main purpose To evaluate the safety and tolerability of LBL-007 combined with toripalimab in the treatment of unresectable or metastatic melanoma, and provide guidance for subsequent clinical studies. To evaluate the safety and tolerability of LBL-007 combined with toripalimab and axitinib in the treatment of unresectable or metastatic melanoma, and provide guidance for subsequent clinical studies. Secondary purpose To evaluate the preliminary efficacy of LBL-007 combined with toripalimab in the treatment of unresectable or metastatic melanoma; To evaluate the preliminary efficacy of LBL-007 combined with toripalimab and axitinib in the treatment of unresectable or metastatic melanoma; To evaluate the PK characteristics of LBL-007 combined with toripalimab in the treatment of unresectable or metastatic melanoma; To evaluate the PK characteristics of LBL-007 combined with toripalimab and axitinib in the treatment of unresectable or metastatic melanoma; To evaluate the LAG-3 receptor occupancy (RO) before and after medication and its relationship with efficacy; To evaluate the immunogenicity of LBL-007 in melanoma patients Exploratory purpose To evaluate the expression of lymphocyte subsets, LAG-3 and PD-L1 in tumor tissues before and after treatment and their correlation with efficacy; To evaluate the correlation between immune cell activation markers perforin or granzyme, and transcription factor 7 (TCF7) and efficacy; To evaluate the expression of VEGF-A in tumor tissues before and after treatment and its correlation with efficacy (applicable to the LBL-007 combined with toripalimab and axitinib group).